{
  "patent_number": "US 20230076417",
  "country": "US",
  "title": "Targeting Cancer Cells with Smart, Internalizing Antibodies",
  "original_title": "Multispecific antigen-binding molecule with improved internalization characteristics",
  "summary": "This patent describes a special antibody with two binding parts, one that finds a cancer target and another that helps the whole molecule get pulled inside the cancer cell more effectively, especially when the target is present.",
  "what_it_does": "This patent describes a special molecule, like an antibody, that has two specific parts, called antigen-binding domains. The first part is designed to attach to a 'target molecule (T)' often found on cancer cells (Claim 1). The second part attaches to an 'internalizing effector protein (E)' (Claim 1), which is a protein on the cell surface that helps pull things inside. The key feature is that this second part has a very specific binding strength, or 'dissociation constant (KD),' for the effector protein (E), set between 10^-9 and 10^-8 M (Claim 1). This precise binding strength helps the entire molecule get pulled into the cell more efficiently, especially when the target molecule (T) is also present (Claim 8, 10). For example, a HER2xCD63 bispecific antibody (Claim 36) could be designed to deliver a drug inside HER2-positive cancer cells.",
  "what_it_does_not_cover": [
    "Antibodies that only bind to one target (monospecific antibodies), as it requires a 'first antigen-binding domain and a second antigen-binding domain' (Claim 1).",
    "Multispecific antibodies where the second binding domain's affinity (KD) for the internalizing effector protein (E) is outside the specified 10^-9 to 10^-8 M range (Claim 1).",
    "Molecules that internalize into cells without requiring the presence of the target molecule (T) for enhanced internalization (Claim 8).",
    "Molecules where the effector protein (E) is not a cell surface molecule that is internalized into the cell (Claim 7).",
    "Molecules where the target (T) is not associated with a tumor or cancer (Abstract, Claim 35)."
  ],
  "filed": "2022-04-06",
  "granted": null,
  "expires": "2042-04-06",
  "status": "active",
  "holder": "Genmab AS",
  "holder_url": "https://patentbrief.org/company/genmab-as",
  "inventors": [
    {
      "name": "Joost MELIS",
      "url": "https://patentbrief.org/inventor/joost-melis"
    },
    {
      "name": "Tom Vink",
      "url": "https://patentbrief.org/inventor/tom-vink"
    },
    {
      "name": "Esther BREIJ",
      "url": "https://patentbrief.org/inventor/esther-breij"
    },
    {
      "name": "Paul Parren",
      "url": "https://patentbrief.org/inventor/paul-parren"
    },
    {
      "name": "Bart De Goeij",
      "url": "https://patentbrief.org/inventor/bart-de-goeij"
    },
    {
      "name": "Hendrik TEN NAPEL",
      "url": "https://patentbrief.org/inventor/hendrik-ten-napel"
    },
    {
      "name": "David Satijn",
      "url": "https://patentbrief.org/inventor/david-satijn"
    }
  ],
  "times_cited": 1,
  "tags": [
    "biotech",
    "pharmaceutical",
    "oncology"
  ],
  "abstract": "The present invention relates to a multispecific antigen-binding molecule comprising a first antigen-binding domain and a second antigen-binding domain. The first domain specifically binds a target molecule (T), and the second domain specifically binds an internalizing effector protein (E), the second antigen-binding domain having a dissociation constant (KD) with E of between 10−9 and 10−8 M. The multispecific antigen-binding molecule is useful in a method for treating and/or preventing a cancer.",
  "url": "https://patentbrief.org/patent/us/20230076417/multispecific-antigen-binding-molecule-with-improved-internalization-characteris",
  "markdown_url": "https://patentbrief.org/patent/us/20230076417/multispecific-antigen-binding-molecule-with-improved-internalization-characteris/md",
  "google_patents_url": "https://patents.google.com/patent/US20230076417",
  "relatedPatents": [
    {
      "patentNumber": "20210055304",
      "countryCode": "US",
      "title": "How to Measure Unbound Drug Target in a Sample",
      "url": "https://patentbrief.org/patent/us/20210055304/method-for-the-detection-of-a-binding-partner-of-a-multispecific-binder"
    },
    {
      "patentNumber": "10138293",
      "countryCode": "US",
      "title": "How Roche Engineers Antibodies to Target Two Different Diseases Simultaneously",
      "url": "https://patentbrief.org/patent/us/10138293/opdivo-nivolumab"
    },
    {
      "patentNumber": "20210301031",
      "countryCode": "US",
      "title": "Targeted Cancer Drugs Using Antibodies and Polymer Scaffolds",
      "url": "https://patentbrief.org/patent/us/20210301031/napi2b-targeted-antibody-drug-conjugates-and-methods-of-use-thereof"
    },
    {
      "patentNumber": "20210205465",
      "countryCode": "US",
      "title": "Targeting Bad Cells with Toxic Antibodies for Cancer and Autoimmune Disease",
      "url": "https://patentbrief.org/patent/us/20210205465/aberrant-cell-restricted-immunoglobulins-provided-with-a-toxic-moiety"
    },
    {
      "patentNumber": "10772965",
      "countryCode": "US",
      "title": "A Chemical Linker for Attaching Drugs to Antibodies",
      "url": "https://patentbrief.org/patent/us/10772965/covalent-linkers-in-antibody-drug-conjugates-and-methods-of-making-and-using-the"
    }
  ]
}